David Brian Perez bought NEO once, on May 5, 2025

Perez David Brian (also reported as David Brian Perez) is a corporate insider and Director at NeoGenomics, Inc. (NEO), a leading oncology testing and contract research services company.( As a board member, he participates in the company’s governance and strategic oversight, drawing on more than 40 years of executive leadership experience in medical devices and healthcare services, including a long tenure as President and CEO of Terumo BCT, a global biomedical company focused on blood banking, transfusion medicine and cell-based therapies.( In his director role at NeoGenomics, he has reported multiple equity compensation transactions, including the exercise of restricted stock units and receipt of new RSU and stock option grants, and he holds both direct and indirect share ownership in the company through personal holdings and the Perez Joint Revocable Trust.(

Perez’s broader career includes service as Chairman of the Board at Nova Biomedical and Laborie and board memberships at companies such as Mölnlycke and NeoGenomics, where he advises on strategy, growth, and corporate governance.( Over nearly two decades at Terumo BCT, he led the transformation of the business from a single-site operation into a multinational organization with multiple R&D centers and manufacturing plants, helping drive global revenue from approximately $160 million to $1 billion before retiring from his CEO role in 2019.( He now serves as an independent board member and advisor to public, private equity–backed, and non-profit organizations, and holds a BA in Political Science from Texas Tech University, underscoring a background that combines policy awareness with extensive operational and leadership experience in highly regulated global healthcare markets.(

Written by Perplexity from public sources.